Immatics at Immuno-Oncology Summit 2017 (Aug 28 – Sept 1) in Boston, MA, USA

Meet people from Immatics at Immuno-Oncology Summit 2017!
Immatics will be participating in the “Adoptive T Cell Therapy” track and introducing its two adoptive cell therapy programs directed against XPRESIDENT® derived tumor targets:

Wednesday, Aug 30
9am – 9.30am
“Personalized Adoptive Cell Therapy Using Novel XPRESIDENT® Derived Targets”
Ali Mohamed (VP of CMC), Immatics US

For further information please contact us!
For more information on Immuno-Oncology Summit 2017: click